Australian company Pharmaxis (ASX:PXS) says positive results from studies of its oral anti‐fibrotic LOX inhibitor PXS‐5505 mean it is now progressing to a phase 2 study for the treatment of the rare bone cancer, myelofibrosis. …
Latest Video
New Stories
-
Is there any example of another review or inquiry taking this long?
April 10, 2026 - - Latest News -
Rewriting the rules of PBS negotiations to deliver a patient-first reset
April 10, 2026 - - Latest News -
A decade of readiness as AVITA medical expands burn response capability
April 9, 2026 - - Australian Biotech -
Moderna names Carolyn Tucek-Szabo to lead Australia and New Zealand operations
April 9, 2026 - - Latest News -
New Zealand's Pharmac announces a shift in treatment for blood cancer
April 9, 2026 - - Latest News -
It is imperative to very carefully read what the minister said, and then read it again
April 9, 2026 - - Latest News -
Stuart Dignam joins MTPConnect board as it embarks on its second decade
April 8, 2026 - - Latest News